A single-center, open-label, Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy

Trial Profile

A single-center, open-label, Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy

Planning
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Poloxamer 188 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 New trial record
    • 14 Sep 2017 According to a Phrixus Pharmaceuticals media release, the National Heart Lung and Blood Institute will provide the drug product and Charley's Fund and Team Joseph led the funding of this trial, with significant support from Harrisons Fund, Hope for Gus, JBs Keys to DMD, Little Hercules, and Michael's Cause.
    • 14 Sep 2017 According to a Phrixus Pharmaceuticals media release, Dr. John L. Jefferies will be the Principal Investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top